Product Briefs: IPF Breakthroughs, Bigger Labels For Velcade And Lymphoseek, Acura Appeal Denied
Executive Summary
Roche’s Esbriet and Boehringer’s Ofev become the first drugs approved by FDA for idiopathic pulmonary fibrosis; Velcade approved for first-line mantle cell lymphoma; Lymphoseek cleared for solid tumors; Acura mulls next steps after losing appeal on abuse-deterrent claim for Vycavert.
You may also be interested in...
Two Treatments For IPF Edge Closer To Market, Will Come Down To Subtle Differences
InterMune’s pirfenidone and Boehringer Ingelheim’s nintedanib are neck-and-neck in the race to be the first drug interventions in the U.S. for the fatal lung disease. Phase III data from both drugs were presented at the American Thoracic Society meeting and published in the NEJM May 18.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.